Erenumab

Limits on what this shows

• Why no grade: Dual condition met: no Tier B/C evidence was opened and verified to support even a yellow grade, and no circulating consumer claim about erenumab and mitochondrial function was identified to rebut as white.

Channels tried, this pass

Crossref API query ("calcitonin gene-related peptide mitochondria oxidative phosphorylation") returned on-topic mitochondrial-biology results but none connecting any CGRP drug to mitochondrial structure or function, a clean zero rather than a blocked attempt. A second Crossref query ("CGRP receptor antagonist mitochondrial biogenesis PGC-1") returned a general PGC-1alpha review and a CGRP-antagonist medicinal-chemistry synthesis paper, neither touching mitochondrial biogenesis in a CGRP-drug context, also a clean zero. A third query ("anti-CGRP monoclonal antibody mitochondrial dysfunction migraine") surfaced one candidate, opened and verified directly: Kaltseis et al. 2022, Frontiers in Neurology, DOI 10.3389/fneur.2022.958463, a case report of galcanezumab (not erenumab) used in a migraine patient who already carried a diagnosed mitochondrial SSBP1 mutation; the paper reports migraine-efficacy and cardiovascular-safety outcomes only, states no assessment of the patient's mitochondrial function itself, and does not propose any mechanism by which the antibody affects mitochondria. It was excluded as a tolerability report, not a mitochondrial-burden signal, the same disposition the fremanezumab dossier in this batch gave to a similar galcanezumab case report (Silvestro et al. 2023) in patients with pre-existing mitochondrial disease. Direct WebFetch attempts to Europe PMC (robots.txt disallowed this pass) and to PMC article pages (reCAPTCHA interstitial) could not be completed. Semantic Scholar and OpenAlex API queries returned HTTP 429. General search engines (DuckDuckGo, Bing, Ecosia) all refused the fetch at the robots.txt stage. This session's WebSearch quota (200 of 200 calls used) was exhausted before this repair pass began, so no new WebSearch queries could run for this category.

Limits on what this shows

• Key negative/null findings: Two of the three biomarkers measured, both reflecting antioxidant capacity rather than oxidative damage, showed no change, so this is not evidence of broadly improved or worsened antioxidant status, only of lower circulating protein-oxidation products.
• At-risk subgroups: None identified; the study explicitly states its sample size precludes sub-population analysis by individual antibody.

Regulatory status

Not an FDA-labeled effect; not mentioned in the prescribing information.

Population evidence

Prospective, observational, real-life study, n=42 (erenumab 70 mg n=23, 54.8% of cohort; galcanezumab n=17; fremanezumab 225 mg n=2), with visits at baseline and 1, 3, and 6 months. AOPP (advanced oxidation protein products, a marker of protein oxidative damage): median 291.4 to 236.2 nmol/L, approximately a 19% reduction, p=0.004. FRAP (ferric-reducing antioxidant power) and free sulfhydryl groups (both antioxidant-capacity markers): no significant change from baseline, p>0.05 for each.

Mechanism

Not established in the source. Plausible candidates include reduced neurogenic/trigeminovascular inflammatory activity accompanying fewer migraine attacks, rather than a direct antioxidant action of the antibody itself; no mechanism specific to erenumab's molecular action on oxidative pathways is named in the literature reviewed.

Counter-evidence held on record

Pre/post design with no placebo or non-mAb comparator arm, so part of the change could reflect regression to the mean, seasonal variation, or the general clinical improvement that accompanies any effective migraine-preventive treatment rather than a specific biochemical action of erenumab. The authors do not report results stratified by individual antibody, so attribution to erenumab specifically (rather than to galcanezumab or fremanezumab, also in the cohort) cannot be confirmed from this source. This is a protective, reverse-direction signal, not a deficiency. No antioxidant or supplement recommendation is implied or supported by this finding.

Limits on what this shows

• Key negative/null findings: No erenumab trial safety summary reviewed for this dossier reports anemia or iron deficiency as a treatment-emergent signal; the AIMOVIG label's specific-populations section does not mention iron status.
• At-risk subgroups: Pre-existing iron deficiency is common in migraine patients broadly, particularly menstruating women, independent of which prophylactic therapy, if any, they receive.

Regulatory status

Not addressed anywhere in the AIMOVIG label. Iron is not a named interaction or monitoring parameter.

Population evidence

Al-Qassab et al., 2024, Cureus, DOI 10.7759/cureus.69652, a narrative literature review (opened and verified in full via its open-access PDF), reports prevalence figures drawn from the primary studies it synthesizes: approximately 26.3% of chronic-migraine patients with iron-deficiency anemia (IDA) versus 20% in non-chronic-migraine patients in one cited study (Gur-Ozmen et al.); 22% of female migraine patients with IDA versus 3.9% of controls in another (Tayyebi et al.); and 53.1% of young female migraineurs with IDA in a third (Rashid et al.). No CGRP monoclonal antibody, erenumab, or any specific migraine-prophylaxis drug appears anywhere in the review's scope; this is disease-epidemiology literature, not drug-safety literature, and does not pass the Step 4 cohort test above Tier C/D for erenumab specifically.

Mechanism

None specific to erenumab. The review's proposed mechanisms concern iron's general roles in neurovascular function, oxidative stress (lower superoxide dismutase and higher malondialdehyde reported in iron-deficient migraineurs in the sources it cites), and oxygen transport and energy metabolism, unrelated to CGRP-receptor pharmacology.

Counter-evidence held on record

Confounding by indication is the default explanation here (Hard Rule 6): any iron deficiency observed in an erenumab-treated migraine population is, on current evidence, attributable to the underlying migraine population's baseline iron status, not to the drug. This is a population-context flag, not an erenumab-specific deficiency claim. Do not attribute a patient's iron deficiency to erenumab therapy; evaluate it the same way it would be evaluated in any migraine patient, drug-treated or not.

Limits on what this shows

• Why no grade: Dual condition met: no Tier B/C evidence was opened and verified, and no circulating claim naming erenumab and copper was identified.

Channels tried, this pass

Crossref API query ("migraine CGRP monoclonal antibody copper zinc trace mineral serum") returned a clean zero: the results returned were on-topic for CGRP monoclonal antibodies generally (efficacy, safety, pharmacokinetics, tolerability) but none mentioned copper, zinc, or any trace-mineral status, meaning the query completed and the absence is a genuine literature gap at the time of writing, not a failed fetch. PubMed/PMC search-listing pages and the Europe PMC REST API were rejected by the organization's outbound network proxy (HTTP 403, confirmed via the proxy status log). DailyMed was also rejected (HTTP 403) when re-queried this pass. Semantic Scholar and OpenAlex API queries returned HTTP 429. General search engines (DuckDuckGo, Bing, Ecosia) all refused the fetch at the robots.txt stage. This session's WebSearch quota was already exhausted before this repair pass began.

Limits on what this shows

• Key negative/null findings: A dedicated Crossref search for "erenumab gut microbiome" returned no erenumab-specific or CGRP-monoclonal-antibody-specific result; no study identified in this review, for erenumab or any class member, has directly measured gut microbiome composition, diversity, or function.
• At-risk subgroups: Patients with pre-existing constipation or slow-transit GI disorders, per the general caution implied by the label's postmarketing severe-complication reports.

Regulatory status

AIMOVIG label §5.2: "Constipation with serious complications has been reported following the use of AIMOVIG in the postmarketing setting. There were cases that required hospitalization, including cases where surgery was necessary." Clinical-trial frequency: 1% at 70 mg, 3% at 140 mg, versus 1% placebo during the first 3 months (label Table 1), making constipation one of the most common labeled adverse reactions.

Population evidence

Holzer and Holzer-Petsche, Frontiers in Physiology, 2021/2022, DOI 10.3389/fphys.2021.820006, a mechanistic review that discusses erenumab by name and reports real-world postmarketing constipation rates "may affect more than 50% of patients receiving erenumab," with a dose-dependent effect most prominent at the start of treatment. This is a review, not a new primary dataset, and the real-world figure traces to postmarketing/registry sources cited within it rather than to a randomized trial of erenumab itself.

Mechanism

Named and erenumab-relevant: CGRP is a major enteric sensory-neuron messenger that activates ascending excitatory and descending inhibitory pathways enabling peristaltic motor activity, and separately stimulates ion and water secretion into the intestinal lumen; together these are described as CGRP's "motor-stimulating and prosecretory" actions, which accelerate intestinal transit under normal physiology. Blocking the CGRP receptor, erenumab's specific mechanism, removes this tone. The extension from altered transit to actual gut microbial composition change is physiologically plausible (longer dwell time can alter bacterial fermentation substrate and short-chain-fatty-acid handling) but unconfirmed for this or any CGRP antibody.

Counter-evidence held on record

The clinical-trial constipation rate (1 to 3%) and the real-world rate cited in the Holzer review (above 50%) differ by an order of magnitude, consistent with real-world postmarketing surveillance generally over-capturing mild or self-reported symptoms relative to a controlled trial, and the review itself is not a new primary dataset. No microbiome-sequencing or stool-composition study exists for erenumab or any CGRP monoclonal antibody despite a genuine multi-channel search this pass (Crossref, Frontiers, Europe PMC, PMC, general search engines). The constipation itself is the drug's own documented pharmacodynamic effect, not a nutrient deficiency, and is not separately graded here (Hard Rule 2). Only the unstudied, theoretical microbiome-composition extension is captured in this entry. No probiotic, prebiotic, or fiber supplement dose is recommended on the basis of this entry; persistent or severe constipation on erenumab is a labeled reason to contact the prescriber.

Limits on what this shows

• Key negative/null findings: No source reviewed measured or reported a change in hemoglobin, hematocrit, red-cell mass, or any tissue-hypoxia marker for erenumab; this is a vasomotor effect, not a blood oxygen-carrying-capacity effect.
• At-risk subgroups: Patients with pre-existing Raynaud's phenomenon or other vasospastic disease; the label specifically flags worsening of pre-existing Raynaud's.

Regulatory status

FDA label Warnings and Precautions §5.3 (new-onset or worsening hypertension, often within 7 days of dosing, monitor blood pressure, consider discontinuation) and §5.4 (development, recurrence, or worsening of Raynaud's phenomenon, median symptom onset 71 days, discontinue if symptoms develop).

Population evidence

Saudi Food and Drug Authority pharmacovigilance safety-signal review (2022), 58 individual case safety reports for erenumab and Raynaud's phenomenon as of May 2022; among cases with adequate completeness, 1 assessed as probable and 7 as possible association; 2 cases showed positive dechallenge (improvement after stopping the drug, one improving roughly 70% after months of worsening). Disproportionality analysis Information Component 3.1, read by the source as a positive statistical association. Clinical-trial incidence of Raynaud's phenomenon was under 0.1%, well below the spontaneous-report signal, consistent with reporting bias typical of pharmacovigilance databases.

Mechanism

Named and drug-specific: CGRP receptor antagonism removes a normal vasodilatory tone in peripheral vessels, favoring vasoconstriction or vasospasm under provocation such as cold exposure.

Counter-evidence held on record

Clinical-trial incidence (<0.1%) is far lower than the pharmacovigilance-database signal would suggest, consistent with reporting bias rather than a high true event rate. Per this protocol's rule against grading a drug's own intended or labeled pharmacology as a nutrient deficiency, this entry is a mechanism clarification, not a nutrient-oxygen-delivery deficiency claim. No iron, B12, or other hematologic supplement is implicated. Monitor blood pressure and peripheral circulation symptoms clinically per the label, not through diet or supplementation.

Limits on what this shows

• Key negative/null findings: A dedicated Crossref search for CGRP-receptor-antagonist mitochondrial biogenesis and PGC-1alpha pathways returned no erenumab or CGRP-drug-specific result; no human energy-metabolism or metabolic-panel signal for erenumab was located in this review.
• At-risk subgroups: None identified.

Regulatory status

Not addressed in the AIMOVIG label; not a recognized adverse-effect category.

Population evidence

None in humans and none in erenumab-treated patients specifically. The only supporting data are rodent and mechanistic, described in Ramirez-Exposito, Cueto-Urena, and Martinez-Martos, 2026, Int J Mol Sci 27(11):4973, DOI 10.3390/ijms27114973 (opened and verified directly): "endogenous CGRP contributes to high-fat-diet-induced weight gain by inhibiting sympathetic activity and reducing energy expenditure; its blockade improves insulin sensitivity and reduces adiposity in murine obesity models."

Mechanism

Class-level and mechanistic, not isolated to receptor-versus-ligand blockade: the review describes "blockade" of CGRP signaling broadly (genetic or pharmacologic, in mice) without separately testing a CGRP-receptor antagonist against a CGRP-ligand antibody, and the cohort is mice, not any drug's human clinical population, so this is Tier C/B for erenumab specifically under the cohort test. Erenumab is named elsewhere in the same review for migraine treatment and safety, but not in connection with this energy-metabolism finding.

Counter-evidence held on record

No human clinical confirmation exists in either direction; the rodent mechanism may not translate to this antibody or to humans, and no erenumab trial has reported a metabolic-panel or energy-expenditure finding. Reverse-direction and purely theoretical; this is explicitly not a basis for any ATP-support or energy supplement recommendation.